

Physical activity is associated with improved bone health in children with inflammatory bowel disease.

Jeremy Vanhelst, Florian Vidal, Dominique Turck, Elodie Drumez, Djamel Djeddi, Eve Devouge, Claire Spyckerelle, Serge Ganga Zandzou, Céline Legrand, Laurent Michaud, et al.

► **To cite this version:**

Jeremy Vanhelst, Florian Vidal, Dominique Turck, Elodie Drumez, Djamel Djeddi, et al.. Physical activity is associated with improved bone health in children with inflammatory bowel disease.. Clinical nutrition (Edinburgh, Scotland), 2020, Clinical nutrition (Edinburgh, Scotland), 39 (6), pp.1793-1798. 10.1016/j.clnu.2019.07.018. . hal-03154714

HAL Id: hal-03154714

<https://hal.univ-lille.fr/hal-03154714>

Submitted on 1 Mar 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Article title:** Physical activity is associated with improved bone health in children with
2 inflammatory bowel disease

3 **Short running head:** Bone health and physical activity

4 Jérémy Vanhelst¹, Florian Vidal¹, Dominique Turck^{1,2}, Elodie Drumez³, Djamal Djeddi⁴, Eve
5 Devouge⁵, Claire Spyckerelle⁶, Serge Ganga Zandzou⁷, Céline Legrand⁸, Laurent
6 Michaud^{1,2†}, Laurent Béghin¹, Frédéric Gottrand^{1,2}, Stéphanie Coopman^{1,2}, Delphine Ley^{1,2}

7

8

9 **Abbreviations:** Body Mass Index (BMI), Bone Mineral Density (BMD), Crohn's Disease
10 (CD), Inflammatory Bowel Disease (IBD), Physical Activity (PA), Moderate-to-Vigorous
11 Physical Activity (MVPA), Ulcerative Colitis (UC).

12 † This work is dedicated to the memory of Dr Laurent Michaud.

13

14

15

16

Abstract

17 **Background & Aims:** Bone health is an important concern in patients with inflammatory
18 bowel disease (IBD). Low bone mineral density (BMD) is a powerful predictor of fracture
19 risk in IBD patients. Physical activity (PA) plays an important role in bone health. However,
20 PA data for children and adolescents with IBD are scarce. The primary aim is to evaluate the
21 relationship between PA and BMD in children with IBD. The secondary aim was to assess the
22 relationship between PA and quality of life.

23 **Methods:** Eighty-four IBD pediatric patients (45 boys) aged 14.3 ± 2.7 years were included
24 (disease activity: (i) remission, n=62; (ii) mild, n=18; (iii) severe disease, n=1). BMD was
25 measured using dual-energy X-ray absorptiometry and expressed as age- and sex-based Z-
26 scores. Each patient wore a triaxial accelerometer for seven consecutive days for objective PA
27 quantification. Quality of life was assessed using the PedsQL™ and energy intake was
28 assessed prospectively for three days using a dietary diary.

29 **Results:** BMD Z-score was -0.96 ± 1.11 . Only five patients (6%) fulfilled the
30 recommendation of 60 min of daily moderate-to-vigorous PA (MVPA). The proportion of
31 children with osteopenia and osteoporosis was 51% and 4%, respectively. After adjustment
32 for confounders (pubertal status and body mass index), total PA and time in MVPA were
33 positively associated with BMD (regression coefficient per one standard deviation increase in
34 PA parameters=0.26; $P<0.05$). There was no association between time spent in MVPA and
35 total PA, and total quality of life score.

36 **Conclusions:** PA likely is associated with improved bone health in IBD children. Intervention
37 studies investigating a causal relationship between PA and BMD in pediatric patients with
38 IBD are warranted.

39 **Keywords:** Lifestyle habits, bone mineral density, pediatrics, inflammation.

41 INTRODUCTION

42 Inflammatory bowel diseases (IBDs), including Crohn's disease (CD), ulcerative colitis (UC)
43 and IBD-unclassified (IBD-U), are characterised by chronic inflammation of the
44 gastrointestinal tract. Over the past 50 years, the incidence of IBD has increased globally,
45 with the highest increase in industrialised countries [1]. During the last 25 years, the incidence
46 of IBD has increased dramatically among teenagers in northern France, with an increase of
47 126% and 156% for CD and UC, respectively [2].

48 Bone mass acquisition during childhood and adolescence is a major determinant of skeletal
49 health later in life [3]. Bone health is an important concern in patients with IBD. The
50 prevalence of low bone mineral density (BMD) in children and adolescents with IBD ranges
51 from 8% to 65% [4-6]. Bone mineralisation abnormalities in paediatric IBD are associated
52 with the use of corticosteroids, disease activity, low body weight, young age at onset, pubertal
53 delay, vitamin D deficiency, low calcium intake and intestinal malabsorption [7-9]. Low
54 BMD is a powerful predictor of fracture risk in IBD patients [10].

55 Physical activity (PA), widely recognised as an important health determinant, plays an
56 important role in growth and development. Increased participation in moderate-to-vigorous
57 PA (MVPA) has major health benefits, including a lower risk of cardiovascular and
58 pulmonary disease, musculoskeletal disorder, psychiatric, neurological and metabolic disease
59 as well as cancer [11]. According to international PA recommendations, 60 min of MVPA
60 daily are needed to positively impact child and adolescent health [12]. In contrast, a sedentary
61 lifestyle is associated with adverse health consequences and increased morbidity and mortality
62 in adulthood [13]. However, PA data for children and adolescents with IBD are scarce.

63 Thus, the primary aim of the study was to evaluate the relationship between PA and bone
64 health in IBD paediatric patients. The secondary aim was to assess the relationship between
65 PA and quality of life.

66

67 **SUBJECTS AND METHODS**

68 **Study design**

69 From October 2014 to March 2017, consecutive paediatric patients with IBD who were
70 followed in hospitals in northern France were invited to participate in this prospective study.
71 Inclusion criteria were: (i) age 6–18 years; (ii) informed consent signed by the patient and
72 his/her parents; (iii) IBD diagnosis (CD, UC, IBD-U) at least six months prior; and (iv) not
73 currently participating in another biomedical study. Exclusion criteria were: (i) acute or
74 chronic disease (other than IBD) associated with a decrease in PA; and (ii) any recent event
75 (≤ 15 days) that could affect PA. Eighty-four patients were included.

76 Before participating, the study aims and objectives were carefully explained to, and written
77 informed consent obtained from, each patient and his/her parents. The study was approved by
78 the Research Ethics Committee of the University of Lille (Comité de Protection des
79 Personnes, Nord Ouest IV, Lille, France). All procedures were performed according to the
80 ethical standards of the Helsinki Declaration of 1975, as revised in 2008, and European Good
81 Clinical Practice.

82

83 **Measurements**

84 *Physical activity*

85 PA was assessed using accelerometry, an objective method for use with youth [14]. The
86 triaxial accelerometer was the ActiGraph[®] Monitor (Model GT3X; ActiGraph, Pensacola,
87 CA, USA), with dimensions 46 × 33 × 15 mm and weight 19 g. The accelerometer measures
88 acceleration in three spatial dimensions according to vertical (x), antero-posterior (y) and
89 medio-lateral (z) vectors. The vector magnitude (VM) was calculated as: $VM = \sqrt{x^2+y^2+z^2}$.
90 The epoch length was set at 1 sec. A computer was used to initialise and synchronise the
91 accelerometer, which was calibrated based on patient age, height and weight. The GT3x
92 accelerometer has been validated for measuring PA against oxygen consumption and heart
93 rate [15]. The inter-instrument reliability for this device is better for moderate and vigorous
94 activity than for sedentary activity [16]. Consistent with consensus recommendations for
95 assessing PA in youth, patients who did not report at least three days with a minimum of 10
96 hours of PA per day were excluded from analyses [17]. PA activity levels were classified as:
97 sedentary (0–180 counts.15sec⁻¹); light (181–757 counts.15sec⁻¹); moderate (758–1112
98 counts.15sec⁻¹); and vigorous (>1112 counts.15sec⁻¹) [15].

99 Patients wore the accelerometer on their lower back, beneath their clothing, using an elastic
100 belt with adjustable buckle. They were asked to follow their normal daily routine and
101 instructed to remove the device during contact sports, water-based activities (e.g., swimming,
102 showering, bathing) and overnight. The accelerometer was used to record activity over seven
103 consecutive days during free-living conditions. In addition, patients and parents were
104 instructed to keep a PA diary while the patient wore the accelerometer.

105

106 *Bone mineral density and body composition*

107 BMD and body composition (fat mass and fat free mass) were measured with dual-energy X-
108 ray absorptiometry (DEXA; Hologic Corp., Discovery Type, Software 12.6, Bedford, MA,

109 USA). Patients were scanned in the supine position at high resolution. BMD, fat mass and fat
110 free mass were determined based on whole body scan analyses.

111 Because BMD measurements are age- and sex-specific, standardised Z-scores were calculated
112 by subtracting the age- and sex-specific mean and dividing by the standard deviation.
113 According to World Health Organisation recommendations, normal BMD T-scores are ≥ -1
114 standard deviation (SD), osteopenia T-scores < -1 to > -2.5 SD and osteoporosis T-scores
115 ≤ -2.5 [18].

116

117 *Quality of life*

118 The IMPACT III was not used herein because it has not been validated among French youth.
119 Instead, quality of life was assessed with the Pediatric Quality of Life Inventory (PedsQL™)
120 (Version 4.0), which is divided into age groups 5–7 years, 8–12 years and 13–18 years. Each
121 age group version has 23 questions comprising four dimensions: (i) physical functioning; (ii)
122 emotional functioning; (iii) social functioning; and (iv) school functioning. The PedsQL™
123 provides a total score and two subscale dimensions: (i) physical health (physical functioning
124 scale score); and (ii) psychosocial health (emotional, social and school functioning scale
125 scores). For children 8 to 18 years, each question is scored using a 5-point Likert scale
126 ranging from 0 (never) to 4 (almost/always). Appropriate items were reverse scored and total
127 scores were linearly transformed to a 0–100 scale where: 0 = 100; 1 = 75; 2 = 50; 3 = 25; and
128 4 = 0. For children 5 to 7 years, each question is scored using a 3-point Likert scale ranging
129 from 0 (not at all), 2 (sometimes) and 4 (a lot). Higher scores indicate a better quality of life.
130 Based on scoring recommendations, patients replied to at least 50% of the questions.
131 Patients were asked to complete the age-appropriate PedsQL™ forms and rate the degree to
132 which each item had been a problem for them during the past month, on a 5-point Likert scale

133 for children 8 to 18 years and a 3-point Likert scale for children 5 to 7 years. Total score and
134 subscale dimensions are expressed as percentages of the maximum points possible.

135

136 *Energy intake*

137 Energy intake was assessed using a prospective dietary diary for three consecutive days,
138 including one weekend day. Patients were interviewed about the types of foods consumed
139 during the three 24-hour periods. For the greatest precision possible, patients could complete
140 the dietary diary with their parents. The same dietitian reviewed all dietary diaries. Patients
141 were assisted by an instruction manual for food codification, including validated photographs
142 of more than 250 foods represented in three different portion sizes. Foods were presented in
143 three sizes permitting, with intermediate and extreme positions, seven choices of the amount
144 [19]. All quantities were then calculated using KIDMENU[®] software (SHS, Paris, France) to
145 compute energy intake using food composition tables from the French Food Safety Agency
146 [20].

147

148 *Clinical assessment*

149 Each patient underwent a detailed medical examination. Pubertal status was assessed by direct
150 observation according to Tanner and Whitehouse [21]. Body mass was measured to the
151 nearest 0.1 kg using an electronic scale (Seca, Hamburg, Germany) after removal of shoes and
152 heavy outer garments. Height was measured to the nearest 0.1 cm using a stadiometer (Seca,
153 Hamburg, Germany). Body mass index (BMI) was calculated as weight (kg) divided by
154 height² (m²). Patients had a plain radiograph of the left hand; wrist and bone age were
155 expressed in years using the Greulich and Pyle atlas [22]. In addition, 25(OH)vitamin D,
156 haematocrit, C-reactive protein, albumin and erythrocyte sedimentation rate were measured to

157 assess inflammation and calculate disease activity. The Pediatric CD Activity Index (PCDAI)
158 was used for patients with CD and the Pediatric Ulcerative Colitis Activity Index (PUCAI) for
159 patients with UC [23-24]. The PCDAI comprises three domains: (i) history (one-week recall
160 of abdominal pain, stools, patient functioning, general well-being); (ii) laboratory results
161 (haematocrit, erythrocyte sedimentation rate, albumin); and (iii) physical examination
162 (weight, height, abdomen, perirectal disease, extra-intestinal manifestations). The PUCAI
163 comprises six domains: (i) abdominal pain; (ii) rectal bleeding; (iii) stool consistency; (iv)
164 number of stools per 24 hours; (v) nocturnal stools; and (vi) activity level. Remission was
165 defined as scores <10 and mild activity as scores 10–27.5 on the PCDAI and 10–34 on the
166 PUCAI. Values >37.5 on the PCDAI or >34 on the PUCAI indicated moderate to severe
167 activity. Drug therapy, including 5-ASA, corticosteroids, immunomodulators (azathioprine,
168 methotrexate) and anti-TNF therapy (infliximab, adalimumab) was recorded.

169

170 *Sample size calculation and statistical analysis*

171 The study objective was to evaluate the association between PA and BMD in children with
172 IBD. Classification of correlation coefficients was based on Cohen's rule, where <0.3 is weak,
173 0.3 – 0.6 moderate and >0.6 high [25]. Sample size calculation was based on: H_0 : $r = 0$ (no
174 correlation between parameters) vs. H_1 : $r = 0.3$ (average correlation between parameters). For
175 $\alpha = 5\%$ and power = 80%, $N = 84$ participants were needed.

176 Data are presented as counts (percentages) for categorical variables and mean \pm SD or median
177 [range] for quantitative variables. Normality of distribution was assessed visually using
178 histograms and by using the Shapiro–Wilk test. Associations of PA parameters with outcomes
179 (BMD Z-score and quality of life) were analysed using linear regression models with and
180 without adjustment for confounding factors. For each outcome, confounding factors were

181 selected according to bivariate analyses ($p < 0.10$). Associations of each outcome with
182 potential confounding factors were assessed using Student's *t*-test for categorical confounding
183 factors and Pearson (or Spearman's rank) correlation coefficients for quantitative (or ordinal)
184 confounding factors. All statistical tests were done at the two-tailed α level of 0.05. Data were
185 analysed using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).

186

187 **RESULTS**

188 Sample characteristics are presented in Table 1. Mean BMD Z-score (\pm SD) was -0.96 ± 1.11 .
189 The computer analysis of the accelerometer data showed that 82 participants wore the
190 accelerometer during at least three days with a minimum of 10 hours of PA per day. Two
191 participants were excluded from the analysis because of monitoring failure. Only five patients
192 (6%) fulfilled the recommendation of 60 min of MVPA daily. The prevalence of osteopenia
193 and osteoporosis was 51% and 4%, respectively. Drug therapy is also depicted in Table 1.

194

195 Bivariate analyses assessing the relationships between BMD-Z score and potential
196 confounding factors are shown in Table 2. BMI and pubertal status (Tanner grade) were
197 positively associated with BMD Z-score ($p < 0.05$ for both associations).

198 As shown in Table 3, BMD was not significantly related to any of the PA parameters in
199 bivariate analyses. However, after adjustment for confounding factors, total PA and time
200 spent in MVPA were positively associated during the weekdays with BMD ($p = 0.041$ and
201 $p = 0.046$, respectively).

202 The PedsQLTM total score (\pm SD) was 81.6 ± 13.4 . Associations of quality of life score and
203 potential confounding factors are presented in Table 4. A positive significant association was
204 found between pubertal status and quality of life ($r = 0.23$).

205 As shown in Table 5, no significant association was found between time spent in MVPA/total
206 PA and quality of life in multivariable linear regression models adjusted for pubertal status.

207

208 **DISCUSSION**

209 Osteoporosis is a common skeletal disease and is associated with high morbidity and
210 mortality in adulthood [26]. Even if our study shows that mean BMD Z-score of IBD
211 paediatric patients was within normal range, it is of note that osteopenia was found in half of
212 the patients while osteoporosis was rare. BMD-Z score and quality of life score did not differ
213 significantly according to disease severity. Only a non-significant higher quality of life score
214 in children in remission was found compared to children with mild or severe disease (mean:
215 83 ± 13 vs. 76 ± 15 ; $p=0.058$). In relation to our primary objective, the present study shows a
216 positive association between BMD and both amount of PA and time spent in MVPA. This
217 result is consistent with those reported for healthy children [27-28]. Vicente-Rodriguez et al.
218 observed a negative association between sedentary lifestyle and bone health in healthy
219 adolescents. More than three hours daily of sedentary behaviour (e.g., watching TV) was
220 associated with increased risk for low bone mineral content in males [27]. In healthy young
221 adults, PA is associated with improved BMD independent of gender and vitamin D status
222 [28]. To our knowledge, the only study assessing bone health and PA in IBD has been
223 performed in adult patients [29]. Patients were randomised to a control group or a low-impact
224 exercise program with increasing intensity across a 12-month period [29]. In patients who
225 were able to fully comply with the exercise program, the only significant BMD gain was
226 observed at the greater trochanter (+4.7%); these findings were independent of changes in
227 potential confounding variables (e.g., steroid dose, weight, diet).

228 IBD have a well-known negative impact on health-related quality of life (HRQoL) [30]. Ng et
229 al studied PA as non-pharmacological approach in the management of IBD for improving or
230 maintaining HRQoL [31]. Another study showed that adult patients engaged higher volumes
231 of MVPA above 150 min/week and walking, particularly above 60 min/week, improved their
232 quality of life [32]. Similar results have been found in people with other chronic diseases or in
233 healthy people [33-35]. Results from our study do not concur with previous research.

234 According to youth PA guidelines, children and adolescents should accumulate a minimum of
235 60 min of MVPA daily through transportation, physical education, sports, free play and
236 planned exercise for positive health outcomes [12]. A very low proportion of our study
237 sample followed this recommendation. These data are alarming in relation to studies of
238 healthy children [36-37]. In 2004, among 2185 children and adolescents assessed with
239 accelerometry, 90% of boys and 80% of girls achieved health-related PA recommendations
240 [36]. In a population of 2200 European adolescents, 57% of boys and 28% of girls followed
241 the PA recommendations, based on accelerometer [37]. Wekstetter et al. compared PA levels
242 between IBD paediatric patients and healthy controls [38]. The differences in PA duration and
243 number of steps between groups did not reach statistical significance; however, female
244 patients had a significantly shorter duration of PA (in total and moderate level). In our study,
245 between patients in remission and patients with mild or severe disease activity, no difference
246 was found in total PA (158.1 vs 176.4 counts.min⁻¹, p = 0.40) and time spent in MVPA (44.8
247 vs 42.9 min.day⁻¹, p = 0.47).

248 It has been hypothesized that PA could be associated with an increased risk for exacerbation
249 of inflammation [39]. Ploeger et al examined inflammatory cells and cytokines in response to
250 acute bouts of moderate intensity continuous exercise and high intensity intermittent exercise
251 in youth with CD and in healthy matched controls [39]. In CD patients, both types of exercise
252 increased immune cells. Moderate intensity exercise induced a significantly greater increase

253 in leukocytes, neutrophils, lymphocytes, monocytes, IL-6 and IL-17, compared with high
254 intensity exercise. TNF- α did not change significantly with either exercise. These preliminary
255 results suggest that moderate PA of short duration is not associated with a deleterious effect
256 on inflammatory parameters. However, further studies are needed to assess the effects of
257 regular exercise on inflammation in IBD pediatric patients.

258 The current study has both strengths and limitations. Importantly, strong objective methods
259 were used to assess both PA (using accelerometry) and bone health (using DEXA).
260 Additionally, confounding factors were accounted for in the statistical analyses. The study
261 limitations include its observational design, which means that associations cannot be
262 interpreted as causal. Moreover, the sample size did not allow to study the impact of gender
263 on PA, quality of life and BMD-Z score, and to test the heterogeneity in PA and BMD score
264 according to disease severity. Regarding the multiple testing issue, we could not exclude false
265 positive findings. Moreover, we could not exclude bias in estimates due to missing data. In
266 addition, the thresholds used to classify PA may have affected the results, as previously
267 described [40]. Variations in weather conditions (e.g., wind, rain, sunshine) during PA
268 assessments were not recorded but may also have affected our results. Another limitation of
269 our study is the lack of information on the type of PA. Animal data showed that mechanical
270 stress (*i.e.*, mechanical loading) on bone can enhance bone mass [41-44]. Results in healthy
271 adolescents concur with animal studies. PA involving weight bearing (e.g walking, running) is
272 more beneficial to bone mass as compared to PA with minimal weight bearing (e.g cycling,
273 swimming) [45-46]. Another limitation of the current study is that the small sample size did
274 not allow to compare CD patients and UC patients.

275 In summary, PA was found to be positively associated with BMD in paediatric patients with
276 IBD. Intervention studies investigating a causal relationship between PA and BMD are thus
277 warranted in order to determine whether IBD paediatric patients could benefit from PA

278 promotion programs. In addition, these studies should aim at determining the most adequate
279 PA, including type, intensity, duration and frequency.

280

281 Funding sources

282 This work was supported by Lille University Hospital Programme (Fonds hospitalier
283 d'aide à l'émergence et à la structuration des activités et équipes de recherche) (Grant number
284 U5235B012P003). The content of this paper reflects only the authors' views, and the Lille
285 University Hospital is not liable for any use that may be made of the information contained
286 therein.

287

288 Conflict of interest

289 The authors do not have any competing interests.

290

291 Acknowledgements

292 The authors thank the participants for taking part in the study.

293

294

295

296

297

298 **REFERENCES**

- 299 1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing
300 incidence and prevalence of the inflammatory bowel diseases with time, based on systematic
301 review. *Gastroenterology* 2012; 142: 46-54.
- 302 2. Ghione S, Sarter H, Fumery M, Armengol-Debeir L, Savoye G, Ley D, et al. Dramatic
303 increase in incidence of ulcerative colitis and Crohn's disease (1988-2011): A population-
304 based study of French adolescents. *Am J Gastroenterol* 2018; 113: 265-72.
- 305 3. Baxter-Jones AD, Faulkner RA, Forwood M, Mirwald RL, Bailey DA. Bone mineral
306 accrual from 8 to 30 years of age: An estimation of peak bone mass. *J Bone Miner Res* 2011;
307 26: 1729-394.
- 308 4. Ahmed SF, Horrocks IA, Patterson T, Zaidi S, Ling SC, McGragan, et al. Bone mineral
309 assessment by dual energy X-ray absorptiometry in children with inflammatory bowel
310 disease: evaluation by age or bone area. *J Pediatr Gastroenterol Nutr* 2004; 38: 276-80.
- 311 5. Schmidt S, Mellström D, Norjavaara E, Sundh V, Saalman R. Longitudinal assessment of
312 bone mineral density in children and adolescents with inflammatory bowel disease. *J Pediatr*
313 *Gastroenterol Nutr* 2012; 55: 511-8.
- 314 6. Walther F, Fusch C, Radke M, Beckert S, Findeisen A. Osteoporosis in pediatric patients
315 suffering from chronic inflammatory bowel disease with and without steroid treatment. *J*
316 *Pediatr Gastroenterol Nutr* 2006; 43: 42-51.
- 317 7. Schüle S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, et al. Prediction of low bone
318 mineral density in patients with inflammatory bowel diseases. *United European Gastroenterol*
319 *J* 2016; 4: 669-76.

- 320 8. Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low
321 bone density in Crohn's disease. *Inflamm Bowel Dis* 2002; 8: 87-92.
- 322 9. McCarthy D, Duggan P, O'Brien M, Kiely M, McCarthy J, Shanahan F, et al. Seasonality
323 of vitamin D status and bone turnover in patients with Crohn's disease. *Aliment Pharmacol*
324 *Ther* 2005; 21: 1073-83.
- 325 10. Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel
326 disease and their relationship to corticosteroid use: a population based cohort study. *Gut* 2004;
327 53: 251-5.
- 328 11. Pedersen BK, Saltin B. Exercise as medicine - evidence for prescribing exercise as
329 therapy in 26 different chronic diseases. *Scand J Med Sci Sports* 2015; 25: 1-72.
- 330 12. Cale L, Harris J. Exercise recommendations for young people: An update. *Health Educ J*
331 2001; 101: 126–38.
- 332
- 333 13. Saunders TJ, Vallance JK. Screen Time and Health Indicators Among Children and
334 Youth: Current Evidence, Limitations and Future Directions. *Appl Health Econ Health Policy*
335 2017; 15: 323-31.
- 336 14. Vanhelst J, Béghin L, Drumez E, Coopman S, Gottrand F. Awareness of wearing an
337 accelerometer does not affect physical activity in youth. *BMC Med Res Methodol* 2017; 17:
338 99.
- 339 15. Romanzini M, Petroski EL, Ohara D, Dourado AC, Reichert FF. Calibration of ActiGraph
340 GT3X, Actical and RT3 accelerometers in adolescents. *Eur J Sport Sci* 2014; 14: 91-9.

- 341 16. Santos-Lozano A, Marín PJ, Torres-Luque G, Ruiz JR, Lucia A, Garatachea N. Technical
342 variability of the GT3X accelerometer. *Med Eng Phys* 2012; 34: 787-90.
- 343 17. Rich C, Geraci M, Griffiths L, Sera F, Dezateux C, Cortina-Borja M. Quality control
344 methods in accelerometer data processing: defining minimum wear time. *PLoS One* 2013;
345 8:e67206.
- 346 18. WHO Scientific Group on the Prevention and Management of Osteoporosis (2000:
347 Geneva, Switzerland) (2003). "Prevention and management of osteoporosis : report of a WHO
348 scientific group".
- 349 19. Le Moullec N, Deheeger M, Preziosi P, Montero P, Valeix P, Rolland-Cachera MF, et al.
350 Validation du manuel photos utilisé pour l'enquête alimentaire de l'étude SU.VI.MAX. *Cah*
351 *Nutr Diet* 1996 ; 31: 158–64.
- 352 20. AFSAA, CIQUAL, Maisons-Alfort. French Food Composition Data base. REGAL 2007.
353 Informatic Center for Quality of foods. In: INSERM, Editor. Pictures of different meals.
354 Paris: INSERM; 1993: 1–63.
- 355 21. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height
356 velocity, weight velocity, and stages of puberty. *Arch Dis Child* 1976; 51: 170-9.
- 357 22. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist.
358 2nd ed. [reprint]. Stanford: Stanford University Press; 1959.
- 359 23. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al.
360 Development and validation of a pediatric Crohn's disease activity index. *J Pediatr*
361 *Gastroenterol Nutr* 1991; 12: 439-47.

- 362 24. Turner D, Otley AR, Mack D, Hyams J, de Bruine J, Uusoue K, et al. Development,
363 validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective
364 multicenter study. *Gastroenterology* 2007; 133: 423-32.
- 365 25. Cohen J. *Statistical power analysis for the Behavioral sciences*. Eds. Hillsdale: Lawrence
366 Erlbaum Associates, 2nd edn. 1988. p. 455.
- 367 26. Wehren LE, Magaziner J. Hip fracture: risk factors and outcomes. *Curr Osteoporos Rep*
368 2003; 1: 78-85.
- 369 27. Vicente Rodriguez G, Ortega FB, Rey-López JP, España-Romero V, Blay VA, Blay G, et
370 al. Extracurricular physical activity participation modifies the association between high TV
371 watching and low bone mass. *Bone* 2009; 45: 925-30.
- 372 28. Tønnesen R, Schwarz P, Hovind PH, Jensen LT. Physical exercise associated with
373 improved BMD independently of sex and vitamin D levels in young adults. *Eur J Appl*
374 *Physiol* 2016; 116: 1297-304.
- 375 29. Robinson RJ, Krzywicki T, Almond L, al-Azzawi F, Abrams K, Igbal SJ, et al. Effect of a
376 low-impact exercise program on bone mineral density in Crohn's disease: a randomized
377 controlled trial. *Gastroenterology* 1998; 115: 36-41.
- 378 30. Moradkhani A, Beckman LJ, Tabibian JH. Health-related quality of life in inflammatory
379 bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors. *J Crohns*
380 *Colitis* 2013; 7: 467-73.
- 381 31. Ng V, Millard W, Lebrun C, Howard J. Low-intensity exercise improves quality of life in
382 patients with Crohn's disease. *Clin J Sport Med* 2007; 17: 384-8.

- 383 32. Taylor K, Scruggs PW, Balemba OB, Wiest MM, Vella CA. Associations
384 between physical activity, resilience, and quality of life in people with inflammatory bowel
385 disease. *Eur J Appl Physiol*. 2018 Apr;118(4):829-836.
- 386 33. Nathan I, Norton C, Czuber-Dochan W, Forbes A. Exercise in individuals with
387 inflammatory bowel disease. *Gastroenterol Nurs* 2013; 36: 437–42.
- 388
- 389 34. Abell JE, Hootman JM, Zack MM, Moriarty D, Helmick CG. Physical activity and health
390 related quality of life among people with arthritis. *J Epidemiol Commun Health* 2005; 59:
391 380–85.
- 392
- 393 35. Anonyke NK, Trueman P, Green C, Pavey TG, Taylor RS. Physical activity and health
394 related quality of life. *BMC Public Health* 2012; 12: 624–31.
- 395
- 396 36. Riddoch CJ, Bo Andersen L, Wedderkopp N, Harro M, Klasson-Heggebo L, Sardinha LB,
397 et al. Physical activity levels and patterns of 9- and 15-yr-old European children. *Med Sci*
398 *Sports Exerc* 2004; 36: 86-92.
- 399 37. Ruiz JR, Ortega FB, Martínez-Gómez D, Labayen I, Moreno LA, De Bourdeaudhuij I, et
400 al. Objectively measured physical activity and sedentary time in European adolescents: the
401 HELENA study. *Am J Epidemiol* 2011; 174: 173-84.
- 402 38. Werkstetter KJ, Ullrich J, Schatz SB, Prell C, Koletzko B, Koletzko S. Lean body mass,
403 physical activity and quality of life in paediatric patients with inflammatory bowel disease and
404 in healthy controls. *J Crohns Colitis* 2012; 6: 665-73.

- 405 39. Ploeger H, Obeid J, Nguyen T, Takken T, Issenman R, de Greef M, et al. Exercise and
406 inflammation in pediatric Crohn's disease. *Int J Sports Med* 2012; 33: 671-9.
- 407 40. Vanhelst J, Béghin L, Salleron J, Ruiz JR, Ortega FB, Ottevaere C, et al. Impact of the
408 choice of threshold on physical activity patterns in free living conditions among adolescents
409 measured using a uniaxial accelerometer: the HELENA study. *J Sports Sci* 2014; 32: 110-5.
- 410 41. WheWheeler DL, Graves JE, Miller GJ, Vander Griend RE, Wronski TJ, Powers SK, et
411 al. Effects of running on the torsional strength, morphometry, and bone mass of the rat
412 skeleton. *Med Sci Sports Exerc* 1995; 27:520-9.
- 413 42. YinglYingling VR, Davies S, Silva MJ. The effects of repetitive physiologic loading on
414 bone turnover and mechanical properties in adult female and male rats. *Calcif Tissue Int*
415 2001; 68:235-9.
- 416 43. Vavan der Wiel HE, Lips P, Graafmans WC, Danielsen CC, Nauta J, van Lingen A, et al.
417 Additional weight-bearing during exercise is more important than duration of exercise for
418 anabolic stimulus of bone: a study of running exercise in female rats. *Bone* 1995; 16: 73-80.
- 419 44. Notomi T, Okimoto N, Okazaki Y, Tanaka Y, Nakamura T, Suzuki M. Effects of tower
420 climbing exercise on bone mass, strength, and turnover in growing rats. *J Bone Miner Res*
421 2001; 16: 166-74.
- 422 45. González-Agüero A, Olmedillas H, Gómez-Cabello A, Casajús JA, Vicente-Rodríguez G.
423 Bone Structure and Geometric Properties at the Radius and Tibia in Adolescent Endurance-
424 Trained Cyclists. *Clin J Sport Med* 2017; 27: 69-77.

425 46. Gomez-Bruton A, Montero-Marín J, González-Agüero A, Garcia-Campavo J, Moreno
426 LA, Casajus JA, et al. The Effect of Swimming During Childhood and Adolescence on Bone
427 Mineral Density: A Systematic Review and Meta-Analysis. *Sports Med* 2016; 46: 365-79.

428

429

430 **Legends**

431 **Table 1.** Characteristics of the study patients

432 **Table 2.** Associations between BMD_{wb} Z-score and potential confounding factors

433 **Table 3.** Associations between BMD_{wb} Z-score and physical activity

434 **Table 4.** Associations between quality of life and potential confounding factors

435 **Table 5.** Associations between quality of life and physical activity

436

Table 1. Characteristics of the study patients

	N	Values
Boys	84	45 (53.6)
Age (<i>years</i>)	84	14.3 ± 2.7
Height (<i>cm</i>)	84	160 ± 15
Height-Z score (<i>mean ± SD</i>)	84	0.38 ± 1.6
Weight (<i>kg</i>)	84	50 ± 15
Weight-Z score (<i>mean ± SD</i>)	84	0.4 ± 1.2
Body mass index (<i>kg.m⁻²</i>)	84	19.5 ± 3.4
Body mass index-Z score (<i>mean ± SD</i>)	84	0.21 ± 1.3
Pubertal status (Tanner grade)	82	
I		17 (21%)
II		11 (13%)
III		12 (15%)
IV		26 (32%)
V		16 (20%)
Age at diagnosis (<i>years</i>)	83	10.9 ± 2.8
Disease duration (<i>months</i>)	83	34 [range: 17-65]
IBD diagnosis	84	
Crohn's disease		58 (69%)
Ulcerative colitis		16 (19%)
Inflammatory bowel disease-unclassified		10 (12%)
Vitamin D (<i>ng.mL⁻¹</i>)	83	25 [range: 18-32]
C-reactive protein (<i>mg.L⁻¹</i>)	83	2 [range: 2-8]
BMD _{wb} Z-score	78	-0.96 ± 1.11
BMD _{wb} (<i>g.cm⁻²</i>)	79	0.93 ± 0.14
Fat mass (%)	79	22.4 ± 7.9
Fat free mass (%)	79	77.6 ± 7.9
Bone age (<i>years</i>)	82	13.7 ± 2.8
Intensity of disease	81	
I (remission)		62 (77%)
II (mild activity)		18 (22%)
II (moderate to severe activity)		1 (1%)
Corticosteroids ever	84	35 (42%)
Corticosteroids lifetime	83	
I (ever use or usage ≤ 3 months)		55 (66%)
II (usage > 3 months)		28 (34%)
Drug therapy during the study period	84	
Corticosteroids		4 (5%)
5-ASA		28 (33%)
Azathioprine		14 (17%)
Methotrexate		6 (7%)
Anti-TNF therapy		36 (43%)
Energy intake (<i>Kcal.day⁻¹</i>)	82	1748 [range: 1399-2212]
Calcium intake (<i>mg.day⁻¹</i>)	82	580 [range: 429-844]
Phosphorus intake (<i>mg.day⁻¹</i>)	82	652 [range: 481-941]
Fruits and vegetables (<i>Portion.day⁻¹</i>)	82	1.7 [range: 1.0-2.7]
Total PA (<i>counts</i>)	82	163 [range: 124-217]
Sedentary time (<i>min.day⁻¹</i>)	82	554 [range: 488-599]
MVPA (<i>min.day⁻¹</i>)	82	45 [range: 33-66]
Fulfilling PA recommendations	82	5 (6%)
PedsQL™ total score	84	84.8 [range: 75.0-91.3]

437 Values are expressed as count (percentage), mean ± SD or median [IQR].

438 Abbreviations: IBD= Inflammatory bowel diseases ; IQR=interquartile range; BMDwb= Bone
439 Mineral Density of whole body, MVPA= Moderate to Vigorous Physical Activity; PA=physical
440 activity; SD=standard deviation.
441

442

Table 2. Associations between BMD_{wb} Z-score and potential confounding factors

	Values	P
Age (<i>years</i>)	-0.04	0.76
Sex		
Boys	-0.91 ± 1.04	0.70
Girls	-1.01 ± 1.20	
Body mass index	0.54	<0.001
Intensity of disease		
Remission	-0.88 ± 1.12	0.22
Mild to severe activity	-1.25 ± 1.11	
Pubertal status (Tanner grade)	0.27	0.019
Corticosteroids lifetime		
Ever use or usage ≤ 3 months	-0.93 ± 1.10	0.49
Usage > 3 months	-1.11 ± 1.03	
Anti-inflammatory therapy		
No	-0.84 ± 1.34	0.74
Yes	-0.93 ± 0.14	
Age at diagnosis (<i>years</i>)	0.02	0.85
Energy intake (<i>Kcal.day⁻¹</i>)	0.11	0.33
Calcium intake (<i>mg.day⁻¹</i>)	0.09	0.45
Phosphorus intake (<i>mg.day⁻¹</i>)	0.11	0.34
Fruits and vegetables (<i>Portion.day⁻¹</i>)	0.05	0.66
Fat mass (%)	<0.01	0.99
Fat free mass (%)	<0.01	>0.99
Bone age (<i>years</i>)	0.14	0.23
Disease duration (<i>months</i>)	<0.01	0.95
Vitamin D (<i>ng.mL⁻¹</i>)	-0.02	0.85
C-reactive protein (<i>mg.L⁻¹</i>)	-0.02	0.84

443 Values are mean ± standard deviation for categorical variables and correlation coefficient
 444 for continuous variables.

445 BMD_{wb}: Bone Mineral Density of whole body

446

447

Table 3. Associations between BMD_{wb} Z-score and physical activity

	Unadjusted			Adjusted*		
	β (95%CI)	P	R ² (%)	β (95%CI)	P	R ² (%)
All days						
MVPA	0.11 (-0.16 to 0.38)	0.41	0.9	0.19 (-0.05 to 0.44)	0.13	2.5
Sedentary	0.18 (-0.08 to 0.44)	0.16	2.6	0.15 (-0.10 to 0.40)	0.25	1.5
Counts	0.05 (-0.22 to 0.32)	0.72	0.2	0.15 (-0.10 to 0.41)	0.24	1.5
Week days						
MVPA	0.20 (-0.07 to 0.47)	0.14	3.0	0.26 (0.01 to 0.51)	0.041	4.6
Sedentary	0.20 (-0.06 to 0.46)	0.14	3.0	0.18 (-0.08 to 0.44)	0.19	1.9
Counts	0.16 (-0.11 to 0.43)	0.23	1.9	0.26 (0.005 to 0.52)	0.046	4.3
Week end days						
MVPA	0.05 (-0.21 to 0.30)	0.71	0.2	0.15 (-0.08 to 0.39)	0.21	1.7
Sedentary	0.16 (-0.09 to 0.42)	0.21	2.1	0.09 (-0.14 to 0.33)	0.42	0.7
Counts	-0.04 (-0.30 to 0.21)	0.74	0.2	0.07 (-0.17 to 0.31)	0.57	3.6

448 Data analysis was performed on 76 patients without missing data on BMD_{wb} Z-score and physical
449 activity parameters.

450 Abbreviations: BMD_{wb}= Bone Mineral Density of whole body; CI= confidence interval; MVPA=
451 moderate to vigorous physical activity

452 β indicate regression coefficient per one standard deviation increase in PA parameters. R²
453 indicates the squared semi-partial correlation coefficient.

454 * Adjusted for between-group difference in potential confounding factors at p<0.10 in bivariate
455 analyses (body mass index and Tanner grade).

456

457

Table 4. Associations between quality of life and potential confounding factors

	Values	P
Age (<i>years</i>)	0.16	0.14
Sex		0.16
Boys	83.6 ± 10.3	
Girls	79.3 ± 16.1	
Body mass index	0.11	0.32
Intensity of disease		0.058
Remission	83.0 ± 12.7	
Mild to severe activity	76.3 ± 15.5	
Pubertal status (Tanner grade)	0.23	0.039
Corticosteroids lifetime		0.96
Ever use or usage ≤ 3 months	81.4 ± 13.4	
Usage > 3 months	81.5 ± 16.7	
Anti-inflammatory therapy		0.19
No	87.2 ± 10.3	
Yes	81.0 ± 13.6	
Age at diagnosis (<i>years</i>)	0.14	0.19
Energy intake (<i>Kcal.day⁻¹</i>)	0.01	0.91
Fruits and vegetables (<i>Portion.day⁻¹</i>)	0.08	0.46
Fat mass (%)	-0.18	0.11
Fat free mass (%)	0.18	0.11
Disease duration (<i>months</i>)	0.11	0.34

458 Values are mean ± standard deviation for categorical variables and correlation
459 coefficient for continuous variables.

460

461

Table 5. Associations between quality of life and physical activity

	Unadjusted			Adjusted*		
	β (95%CI)	P	R ²	β (95%CI)	P	R ²
Total score						
MVPA	-2.09 (-5.04 to 0.85)	0.16	0.025	-1.47 (-4.61 to 1.67)	0.35	0.011
Counts	-2.71 (-5.63 to 0.21)	0.069	0.041	-2.01 (-5.24 to 1.24)	0.22	0.019
Dimension I						
MVPA	-2.75 (-5.72 to 0.22)	0.069	0.041	-1.73 (-4.83 to 1.38)	0.27	0.015
Counts	-2.98 (-5.94 to -0.03)	0.048	0.048	-1.64 (-4.86 to 1.59)	0.31	0.013
Dimension II						
MVPA	-1.75 (-5.05 to 1.55)	0.30	0.014	-1.34 (-4.87 to 2.20)	0.45	0.007
Counts	-2.56 (-5.83 to 0.71)	0.12	0.029	-2.20 (-5.85 to 1.45)	0.23	0.019

462 Data analysis was performed on 82 patients without missing data on PedsQL™ total and

463 physical activity parameters (calculated for all days).

464 Abbreviations: CI= confidence interval; MVPA= moderate to vigorous physical activity.

465 Dimension I: physical health comprising of the physical functioning scale score

466 Dimension II: psychosocial health comprising of the emotional, social and school functioning scales score

467 β indicates regression coefficient per one standard deviation increase in PA parameters.

468 * Adjusted for between-group difference in potential confounding factors at $p < 0.10$ in bivariate

469 analyses (Tanner Grade and Intensity of disease)

470